dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Dyspepsia Diagnosis

History

  • A detailed medical, social (eg smoking and alcohol intake) and family history reduces the differential diagnoses
  • Review medications for possible causes of dyspepsia eg Ca antagonists, nitrates, theophyllines, bisphosphonates, steroids and nonsteroidal anti-inflammatory drugs (NSAIDs), Aspirin, Acarbose, Orlistat, potassium supplements

Physical Examination

  • Often normal except for epigastric tenderness
  • Other PE findings may help diagnose or exclude other diseases eg right upper quadrant pain with cholelithiasis, palpable abdominal mass in hepatoma, lymphadenopathy in gastric malignancy

Laboratory Tests

  • Complete blood counts and chemistries (eg LFTs, pancreatic amylase) may be performed to identify alarm features or metabolic diseases causing dyspepsia or to investigate patients who have been unresponsive to treatment

Complications

Evaluation of Alarm Symptoms 

  • Symptoms that suggest complicated disease must be recognized and patients referred immediately for further diagnostic testing
    • GI bleeding
    • Epigastric mass
    • Iron-deficiency anemia
    • Persistent vomiting
    • Progressive dysphagia
    • Suspicious barium meal
    • Unintentional weight loss
    • Persistent nocturnal symptoms
    • Family history of upper GI cancer
    • Lymphadenopathy
    • Jaundice
    • Painful swallowing

Non-ulcer Dyspepsia or Functional Dyspepsia

  • Patients have >1 bothersome dyspepsia symptoms (eg epigastric pain or burning, early satiety, postprandial fullness) and without evidence of structural disease, including a normal upper endoscopy, that can explain the symptoms
  • Includes subcategories that can overlap: 
    • Postprandial distress syndrome (dyspepsia symptoms caused by meals): Includes 1 or both of the following for at least 3 days/week: Bothersome postprandial fullness or early satiety 
    • Epigastric pain syndrome (dyspepsia symptoms that do not occur exclusively postprandially and can be improved by meals): Includes at least 1 of the following for at least 1 day/week: Bothersome epigastric pain and/or burning   
  • Criteria must be fulfilled for postprandial distress syndrome and/or epigastric pain syndrome and fulfilled for the last 3 months with symptoms starting at least 6 months prior to diagnosis (Rome IV criteria)
  • No evidence is documented on routine evaluation (including upper endoscopy) of organic, systemic or metabolic disease that can explain the symptoms
  • Patients with this diagnosis should be treated similarly as those with uninvestigated dyspepsia provided they meet the following criteria:
    • No heartburn
    • No NSAID or low-dose Aspirin use
    • Normal blood tests
    • No evidence of an abnormality
  • H pylori eradication therapy is effective for patients with H pylori-positive functional dyspepsia 
    • Patients without symptoms 6-12 months following H pylori eradication therapy can be classified as H pylori-associated functional dyspepsia 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).